In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...